AstraZeneca collaborates on cancer nanomedicine

04/22/2013 | PharmaTimes (U.K.)

AstraZeneca and Bind Therapeutics will collaborate on a targeted, programmable, nanotechnology cancer treatment involving a kinase inhibitor. The nanoparticles, which Bind calls Accurins, selectively accumulate, causing higher drug concentrations at the site of a tumor while sparing healthy tissue. AstraZeneca is also working with Horizon Discovery on a kinase therapy that targets the K-Ras mutation in various cancers, including of the lung and colon.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA